NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the Company will present at the LD Micro IX Annual Main Event investor conference being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. from December 6 - 8, 2016. Actinium's Executive Chairman will present at 11:30 AM PST. Details regarding Actinium's presentation are below: Event: LD Micro IX Annual Main Event Conference Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA. Presentation Date: Tuesday, December 6, 2016 Presentation Time: 11:30 AM PST Webcast link: http://wsw.com/webcast/ldmicro11/atnm Actinium's presentation can also be accessed through the investor relations page of the Company's website http://ir.actiniumpharma.com/ir-calendar. It will also be archived and available for playback. Management will participate in 1-on-1 meetings with conference attendees. To schedule a meeting with management please contact Steve O'Loughlin, Vice President, Finance and Corporate Development at email@example.com. About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. ( www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill these cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but preparation for a transplant requires chemotherapy and or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation for patient's seeking a bone marrow transplant that will lead to increased transplant success and survival rates. The Company is currently conducting a 150 patient single, pivotal, multicenter Phase 3 clinical study of Iomab-B in relapsed or refractory acute myeloid leukemia patients (AML) over the age of 55. The Company's second product candidate, Actimab-A, is currently in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial. Actimab-A is being developed to induce remissions in elderly patients with AML patients who lack effective treatment options as they often times cannot tolerate the toxicities of standard frontline therapies. In addition to its clinical programs, Actinium is progressing its alpha-particle immunotherapy (APIT) technology platform that the Company plans to apply to both liquid tumors beyond AML and solid tumors. Forward-Looking Statements for Actinium Pharmaceuticals, Inc. This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact:Actinium Pharmaceuticals, Inc.Steve O'LoughlinVice President, Finance and Corporate Developmentsoloughlin@actiniumpharma.com